Compare MakeMyTrip Ltd (MMYT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Merck & Co., Inc. — how do they compare? MakeMyTrip Ltd trades at $56.43 (market cap $5.05B), while Merck & Co., Inc. trades at $126.24 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 60.8× MakeMyTrip Ltd's market cap, and Merck & Co., Inc. pays a 2.73% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals.
| MMYT | MRK | |
|---|---|---|
Market Cap | $5.05B | $307.25B |
Sector | Technology | Health |
52-Week High | $103.21 | $129.52 |
52-Week Low | $36.30 | $77.60 |
Enterprise Value | $5.69B | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $53.22, down 2.56% on the day, with a bullish technical signal despite recent weakness. The company shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.25 beating expectations of $0.17. Revenue reached $978.34 million in 2025 with a 73.77% gross margin, though 2026 projections indicate margin compression. Analyst sentiment remains positive with 73% buy ratings and a 34% upside target.
The stock presents a growth opportunity with strong operational performance but faces risks from travel disruptions and rising debt levels. While current valuation metrics appear elevated (P/E 147.78), the company's market leadership in Indian online travel and consistent execution support the bullish case. Key risks include competitive pressures and macroeconomic sensitivity to travel demand.
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
